Introduction

The drug-eluting stent (DES) has changed our approach to the management of acute myocardial infarction (AMI) over the past decade. The first commercial DES was a significant innovation because it reduced the numerous drawbacks of the bare-metal stent (BMS), including high in-stent restenosis (ISR) rates with neointimal hyperplasia (NIH) as an underlying mechanism.\(^1\)\(^\text{-}5\) Drugs coating the stents were categorized as cytotoxic agents, such as paclitaxel, a chemotherapy agent in the treatment of breast or gastric cancer, and sirolimus, an anti-inflammatory agent in kidney transplantation, that were used in first-generation DESs. Commonly used second-generation drugs in stents are zotarolimus, an immunosuppressant and semisynthetic derivative of rapamycin, everolimus, a derivative of sirolimus that works as an inhibitor of the mammalian target of rapamycin (mTOR), and biolimus, an equipotent semi-synthetic sirolimus analog with a biodegradable polymer, polylactic acid, with ten times the lipophilicity of sirolimus. All three types of DES have improved clinical outcomes after percutaneous coronary intervention (PCI) by reducing ISR, stent-thrombosis, and the duration of anti-platelet therapy.\(^6\)\(^\text{-}8\)

The Heart Research Center of the Chonnam National University Hospital has investigated the safety and efficacy of various drug-coated stents in both human and animal studies (Fig. 1). Some demonstrated usefulness in avoiding ISR by preventing neo-intimal regrowth. In the present review, we cover imported DESs and the new DESs that have been developed in our center, and provide perspectives on DES development.

Searching for Optimal Coating Materials

Conventional coating materials from western countries

The first generation: paclitaxel and sirolimus

Paclitaxel is a mitotic inhibitor used to treat patients with lung, ovarian, breast, and head and neck cancer, as well as advanced forms of Kaposi’s sarcoma. Sirolimus, also known as rapamycin, is an immunosuppressive drug used to prevent organ rejection after transplantation. It is particularly useful in kidney transplants.\(^9\)}
**The second generation: everolimus and zotarolimus**

Everolimus is the 40-O-2-hydroxyethyl derivative of sirolimus and works similar to sirolimus as an inhibitor of mTOR. It is currently used as an immunosuppressant to prevent organ rejection after transplantation and to treat renal cell carcinoma and other tumors. Zotarolimus is an immunosuppressant and a semi-synthetic derivative of rapamycin. It was designed for use in stents with phosphorylcholine as a carrier.

**Experimental coating materials at Chonnam National University Hospital**

**Heparin**

Heparin, an anticoagulant, can interact with antithrombin III to prevent thrombus formation and activation. Heparinization of surfaces has proven to be a successful strategy in preventing thrombus formation and improving the compatibility of blood-contacting biomaterials. Heparin has anticoagulant properties and inhibits smooth-muscle cell (SMC) proliferation. Local drug delivery with heparin-coated stents can deliver a high concentration of heparin to lesion sites without systemic bleeding complications.

**Abciximab**

At the beginning of the 21st century, investigators in our group examined the effectiveness of abciximab, not only as an adjunctive agent during PCI, but also as an eluting material in the manufacture of coronary stents. Our group conducted many investigations on human as well as animal subjects with the Reopro® (abciximab)-coated stent. The results will be discussed elsewhere in this review. Abciximab, a potent antiplatelet agent that blocks the ultimate pathways to platelet aggregation, improves the outcomes of high-risk PCI and decreases the incidence of major adverse cardiac events. In contrast to other types of platelet glycoprotein IIb/IIIa receptor blockers, it also binds to Mac-1 (CD11b/18) on vascular endothelial cells and macrophages, thereby inhibiting inflammatory responses and SMC proliferation after vascular injury.

**Ramiprilat**

The renin-angiotensin-aldosterone system has been implicated in the pathogenesis of NIH. Angiotensin II has been found to be associated with the migration and proliferation of vascular SMCs in restenotic lesions. Moreover, the administration of angiotensin converting enzyme inhibitors (ACEIs) has been reported as reversing impaired endothelial-dependent responses to acetylcholine in patients with heart failure and hypertension, as well as improving coronary endothelial function after treatment with an ACEI in patients with coronary artery disease (CAD).

**Alpha-lipoic acid**

Alpha-lipoic acid (α-LA) is a potent antioxidant and acts as a co-
factor of key mitochondrial enzymes, such as pyruvate dehydrogenase and α-ketoglutarate dehydrogenase.\textsuperscript{28} α-LA is endogenous and improves diabetes-induced endothelial dysfunction, probably due to its antioxidant effects and direct free-radical scavenging properties.\textsuperscript{30} Moreover, α-LA inhibits the inflammatory pathway and prevents NIH after carotid artery stenting.\textsuperscript{31,32}

**Carvedilol**

Carvedilol is a neurohumoral antagonist with multiple actions. It was originally discovered as a β-adrenoceptor antagonist, but subsequent research revealed that it also possesses potent antioxidant and free-radical scavenger properties. In addition, carvedilol inhibits its vascular smooth muscle cell (VSMC) proliferation induced by a broad group of mitogens, such as platelet-derived growth factor, fibroblast growth factor, endothelin-1, serum, and thrombin, and was found to suppress 84% NIH in a rat carotid injury model.\textsuperscript{33-34} Recent studies have shown that the antimitogenic mechanism of the action of carvedilol on VSMCs involves the inhibition of mitogen-activated protein kinase activity and the regulation of cell cycle progression. Carvedilol is highly lipophilic, which promotes rapid cellular uptake,\textsuperscript{35-36} and a stent containing carvedilol allows a high local concentration of the drug to reach the vessel walls with which it comes into contact.

**Probucol**

Probucol was developed and sold as a lipid-lowering agent and is also used as an antioxidant,\textsuperscript{37} reducing restenosis after percutaneous transluminal coronary angioplasty. It has, furthermore, recently been identified as a vascular protectant.\textsuperscript{38-41} A multicenter study recently reported that post-stenting restenosis was reduced after probucol use via a mechanism that increases the diameter of the vessel lumen.\textsuperscript{42} The combination of probucol and candesartan has potential antioxidant and vascular protectant effects.\textsuperscript{43}

**Fucoidan**

Fucoidan is a sulfated polysaccharide extracted from brown seaweed that reduces rat SMC proliferation in vitro in a more intensive manner than heparin.\textsuperscript{44} Fucoidan inhibits SMC proliferation by reducing mitogen-activated protein kinase activity. Investigators at our center recently succeeded in producing and characterizing new homogeneous fractions of low-molecular-weight fucoidan with low anticoagulant activity. They aimed to establish the optimal conditions for the fucoidan coating on a BMS, verifying both the ability of fucoidan to inhibit vascular SMC proliferation in vitro and the inhibitory effect of a fucoidan-coated stent on ISR in a porcine model.\textsuperscript{45}

**Development of a coating method**

**Dopamine-mediated heparin-coated stent**

In recent decades, typical approaches to surface heparinization, such as layer-by-layer self-assembly and covalent immobilization, have been reported in medical literature.\textsuperscript{46-49} Layer-by-layer self-assembly has a common limitation involving the clinical translation of materials functionalized with biomolecules. That is, these coatings fail to withstand long-term exposure in vivo because of a lack of robustness. Inspired by the composition of adhesive proteins in mussels, Bae et al. used dopamine to form thin and surface-adherent films on a stent surface.\textsuperscript{50} Dopamine performs well as a binding agent for coating inorganic surfaces, including stent materials, and others have reported improved hydrophilicity and a substantial reduction of protein adsorption by dopamine.\textsuperscript{51} Heparin was conjugated to dopamine using N-(3-dimethylaminopropyl)-N0-ethylcarbodiimide and N-hydroxysuccinimide,\textsuperscript{52} and may possibly offer a platform for conjugating secondary drugs, such as anti-proliferative drugs.\textsuperscript{53}

**Titanium dioxide-coating method**

We had discovered that the thin film of titanium dioxide (TiO\(_2\)) was deposited onto a BMS through the plasma-enhanced chemical vapor deposition (PECVD) process. We investigated the potential of TiO\(_2\) as a drug-combining matrix. When deposited at a discharge power of 5 W, the film showed a highly smooth surface with a roughness of 9.4 nm, mechanical stability with good adhesion, and good blood compatibility. The film was surface modified with water plasma to introduce hydroxyl groups on the TiO\(_2\) surface. Drugs were then able to be chemically grafted onto the modified surface through the formation of ester bonds between hydroxyl groups on the modified TiO\(_2\) film, and carboxyl groups in the drugs. When heparin, α-LA, and abciximab were grafted onto the TiO\(_2\)-coated and surface modified stents, the mean engrafted amount was measured at 106.1 mg for α-LA, 32.5 mg for abciximab, and 53.9 mg for heparin. In the in vitro drug release test, heparin and abciximab were released continuously for four weeks, but α-LA exhibited a burst release within six days.\textsuperscript{53}

**Nitrogen oxide-doped titanium dioxide-coated stent**

Titanium dioxide or nitrogen-doped titanium oxide (N-TiO\(_2\)) coatings, \textit{inter alia}, have been studied intensively as biomedical implants for contact with blood in organs, such as heart valves, or in vascular stents, as they inhibit platelet aggregation and fibrin growth. TiO\(_2\) film could be applied as a drug-binding matrix as an alternative to organic polymers in DESs. Drugs can be directly grafted onto a TiO\(_2\) film surface through the chemical bond formation
between functional groups of the drug and -OH groups of plasma modified TiO$_2$ film. N-TiO$_2$ film is especially attractive as a coating material among blood-contacting materials, because of its enhanced blood compatibility.$^{54-56}$

Such films are not yet being used as coating for drug binding matrices in DES. Therefore, we discussed the use of N-TiO$_2$ film coatings for DES as a drug-combining matrix, by investigating the properties of coating films prepared by PECVD and by optimizing the surface modification of the N-TiO$_2$ film coatings. N-TiO$_2$ films were promising alternatives to organic polymers in the preparation of DESs, because grafted heparin and abciximab can be released continuously for three weeks from drug-grafted N-TiO$_2$ stents in in vitro drug release testing.$^{57}$

**Dual-coated stent (abciximab and alpha-lipoic acid)**

Abciximab (Reopro®) is a potent anti-platelet agent, $\alpha$-LA (a potent antioxidant), and acts as a co-factor of key mitochondrial enzymes, such as pyruvate dehydrogenase and $\alpha$-ketoglutarate dehydrogenase.$^{58}$ It improves endothelial function and prevents atherosclerosis-related disease.$^{29}$ We compared the effect of a stent coated with abciximab and $\alpha$-LA with that of BMS in a porcine coronary overstretch restenosis model. The findings are provided elsewhere in the present review.

**Aptamer stent: endothelial progenitor cell capture stent**

Aptamers are oligonucleic acid or peptide molecules that bind to a specific target molecule that are usually selected from a large random sequence pool. However, natural aptamers also exist in riboswitches. Aptamers can be used for both basic research and clinical purposes as macromolecular drugs.

Aptamers can be combined with ribozymes to self-cleave in the presence of their target molecules. These compound molecules have additional research, industrial, and clinical applications. The aptamer stent was specifically designed to promote arterial healing using a coating of oligonucleotides, functioning as endothelial progenitor cell (EPC) attracting messengers. As a result, the aptamer stent captures and sequesters circulating EPCs to the luminal stent surface and theoretically initiates re-endothelialization.$^{59}$

**Results of clinical trials of conventional drug-eluting stents**

**Paclitaxel and sirolimus-eluting stents**

Both the paclitaxel-eluting stent (PES) and sirolimus-eluting stent (SES) have shown enhanced outcomes in terms of repeated revascularization compared with BMS.$^{60}$ However, they were associated with an increased risk of very late stent thrombosis.$^{61,62}$

**Everolimus-eluting stent**

Everolimus eluting stents (EESs) improved clinical outcomes compared to PES in terms of repeat revascularization, myocardial infarction, and stent thrombosis.$^{63,64}$ However, EES and PES displayed similar outcomes in terms of rates of death, myocardial infarction, and repeat revascularization.$^{65,66}$

**Zotarolimus-eluting stent**

Zotarolimus-eluting stents (ZESs) demonstrated a lower risk of myocardial infarction$^{67,68}$ than PES and a similar risk of target-lesion revascularization.$^{69}$ ZES showed comparable outcomes with SES after three years for stent thrombosis, death, and myocardial infarction.$^{70}$

**Animal studies and clinical trials of Chonnam National University Hospital stents**

**Heparin-coated stents**

Heparin-coated stents were compared with control BMS stents in a porcine coronary stent restenosis model with stent over-dilatation injury (stent : artery=1.3 : 1.0). The heparin-coated stent was effective in the prevention of late coronary stent restenosis in a porcine model, indicating a possible relationship with the inhibition of neointimal cell proliferation.$^{61}$ In 2001, Shin et al. showed that heparin-coated stents were safe in the early setting of AMI. No additional heparin infusion after stenting was necessary, potentially reducing the risk of bleeding complications.$^{66}$ In 2004, Madduri et al. reported that the use of a heparin-coated stent resulted in favorable procedural and six-month outcomes, no incidence of stent thrombosis, and overall positive cardiac prognosis at the six-month follow-up.$^{29}$ However, Mehran et al. conducted an internet-based registry examining the efficacy of a heparin-coated stent, and found no significant difference in cardiac death, myocardial infarction, target-lesion revascularization, or stent thrombosis between a heparin-coated stent versus BMS.$^{83}$

**Abciximab-coated stents**

Abciximab-coated stents have been shown to be safe and effective in the prevention of coronary restenosis in humans, as well as in a porcine model.$^{29,71}$ A study of 85 patients undergoing follow-up coronary angiography and an intravascular ultrasound (IVUS) showed only a trend toward a decreased restenosis rate. However, late luminal loss was lower in the abciximab-coated stent group.$^{6}$ In a study of 150 patients, the restenosis and target-vessel restenosis rates of an abciximab-coated stent were lower than those with a conventional BMS.$^{72}$ Later, in a study of 96 patients, follow-up IVUS demonstrated an improved intrastent luminal area and intrastent...
NIH. The ISR rate was lower in the abciximab-coated stent group than in the conventional BMS group. In an examination of 138 stents (69 abciximab-coated stents vs. 69 BMS), the restenosis rate and late loss rate were both lower in the abciximab-coated stent group than in the BMS group. At the follow-up IVUS, the intrastent luminal area was significantly larger, and the intrastent NIH area significantly smaller, in the abciximab-coated stent group than in the BMS group. In addition, abciximab-coated stents demonstrated anti-inflammatory effects in a study using a porcine coronary overstretch restenosis model in a histopathological analysis performed 28 days after stenting with abciximab-coated stents versus SES or PES. However, Kim et al. conducted a prospective randomized study comparing the effects of the abciximab-coated stent in 95 patients with BMS with 93 control patients after a two-year follow-up. The six-month IVUS analysis showed that the area of NIH was significantly smaller in the abciximab-coated stent group than in the control group. Nevertheless, at the two-year clinical follow-up, there were no statistically significant differences between the groups in terms of clinical outcomes.

**Ramiprilat-coated stent**

We examined the anti-proliferative and anti-inflammatory effects of ramiprilat-coated stents in a porcine coronary overstretch restenosis model and observed no significant differences in the injury and inflammation scores between the two groups. Within the neo-intima, most inflammatory cells were lymphohistiocytes. Although the ramiprilat-coated stent did not demonstrate significant inhibitory effects on NIH, this stent showed positive effects on inflammatory reaction and arterial healing, similar to the control stent in a porcine coronary restenosis model.

**Alpha-lipoic acid-coated stent**

Lim et al., in our center, found that α-LA feeding and α-LA-coated stents prevent ISR by inhibiting NIH in a porcine coronary artery restenosis model, possibly by inhibiting the activation of the NF-κb pathway and the proliferation of porcine VSMCs.

**Carvedilol-loaded stents and probucol-coated stents**

Kim et al. utilized BiodivYsio® phosphorylcholine-coated stents, dip-coated with carvedilol (5 mg/mL) or probucol (50 mg/mL) by immersion, in respective methanol solutions. Twenty-four stents (carvedilol=8, probucol=8, and control=8) were placed in twelve pigs. Histopathometrical analysis was performed four weeks later. A histomorphometry of the carvedilol-coated stent group compared with the control group showed that the neointimal area decreased by 42% and the lumen area increased by 20%, resulting in a 43% reduction of the % stenosis area. In the probucol-coated stent group, the lumen area, neointimal area, and % stenosis area did not differ significantly from those of the control group. The carvedilol-coated stent, but not the probucol-coated stent, inhibited NIH in a porcine coronary restenosis model.

**Fucoidan stent**

Fucoidan-coated stents (FCSs, fucoidan 12.5 mg/mL), PESs, and BMSs were implanted in the proximal left anterior descending artery, proximal left circumflex artery, and right coronary artery in a randomized manner in six pigs (three stents placed in three coronary arteries per pig). Histopathological analysis was performed on the 28th day of stenting. No polymer cracks or blotched areas were observed in the dual coating. Proliferation of SMC was inhibited in the fucoidan-treated group (12 μg/mL) compared to the control group. There were no significant differences in the internal elastic lamina, lumen area, neointimal area, or % stenosis area among the three stent groups. On the BMS surface, dual coating was appropriate using fucoidan. Despite the fucoidan inhibited SMC proliferation in vitro, the FCS showed no significant differences in the histopathological analysis performed.

**Abciximab and alpha-lipoic acid (a dual-coated stent)**

Lim et al. examined the anti-proliferative and anti-inflammatory effects of a stent coated with abciximab and α-LA in a porcine coronary overstretch restenosis model. A total of ten pigs were randomized into two groups (ten pigs, ten coronaries in each group), in which the coronary arteries were stented with a dual-coated stent and a BMS (control) after randomization. There was no significant difference in the injury score between the two groups. In the neointima, the lymphohistiocyte count was significantly lower in the dual-coated stent group than in the control stent group. There was no significant difference in the fibrin score between the two groups. The neointima area was not significantly different between the two groups. Although the dual-coated stent with abciximab and α-LA showed no significant difference in terms of the inhibition of NIH when compared with the BMS, it was associated with a reduced inflammatory reaction when compared with the control stent in a porcine coronary restenosis model.

**Endothelial progenitor cell capture stent (an aptamer stent)**

We evaluated the effects of the aptamer-coated stent utilizing six pigs and three different stents: cobalt–chromium (CC) BMS, paclitaxel eluting Taxus PES (Boston Scientific, Natick, MA, USA), and aminopryline and aptamer (AA)-coated stents, implanted in the three epicardial coronary arteries in a random manner at 8 to 10 atm. Stent length and diameter were 18 mm and 3 mm, respectively. After one month, the animals underwent a follow-up coronary angiography.
phy with acetylcholine (10 mL, 3 µg/mL) stimulation tests and were then euthanized for histological analysis. There was only a trend toward a decreased minimal lumen diameter in all stents. Neointimal thickness was lower after the use of Taxus PES. The AA-coated stent group showed a tendency toward a lower incidence of stent thrombosis and endothelial dysfunction compared to the Taxus PES group. However, the inhibition of NIH did not differ between the two groups.²⁵

Future direction: promising stents

Biodegradable polymer stents

Drug-eluting stents made with biodegradable polymers have been shown to improve long-term safety and efficacy compared to SES. DESs with biodegradable polymers demonstrated improved safety, compared to BMS in patients with AMI,⁸⁰ and showed outcomes similar to those with EES in patients with CAD at 1 year.⁸¹

Polymer-free drug-eluting stent

Under the hypothesis that the polymer stent coatings reduce late events, polymer-free DES was developed. BioFreedom stents by Biosensors and drug-filled stents by Medtronics do not require polymer coatings on stents. Rather, the drug-filled stent has numerous elution holes through which the drug exits, thereby controlling drug elution through diffusion physics. Potential advantages are 1) avoidance of long-term late adverse effects that might be attributable to the polymer, 2) improved surface integrity since there is no polymer to be sheared or peeled away from the stent struts, and 3) the need for a shorter duration of dual antiplatelet therapy.

Fully bioresorbable scaffolds

In the near future, bioresorbable drug-eluting vascular scaffolds will be available in our daily practice.²⁸²⁹ It remains to be determined whether these devices will demonstrate enhanced safety and efficacy outcomes compared to current DES.

A promising drug-eluting stent from Chonnam National University Hospital

Gene delivery stents: Akt1 siRNA-embedded stents

Akt1 siRNA was delivered to the cells with enhanced proliferation to suppress the Akt1 protein responsible for cellular proliferation at the mRNA level.⁸⁴ The inhibition of Akt1 decreases the expression of caspase-8 in endothelial cells. Suppression of downstream Akt1 signaling proteins such as Fas ligand results in the stimulation of caspase activity and apoptosis in VSMCs. The specific inhibition of Akt1 protein expression has been reported to retard cell growth.⁸⁵-⁸⁹ To evaluate the usefulness of a gene delivery stent, rabbit iliac artery stenting was performed at our center. VSMC proliferation over the stent was suppressed by the delivery of Akt1 siRNA complexed with a biodegradable disulfide cross-linked polyethyleneimine (ssPEI) polymer on a hyaluronic acid-coated stent surface. The study results confirmed that the rate of restenosis was slower when stents were coated with ssPEI complexed with Akt1 siRNA (Fig. 2).⁸⁴

Drug and gene delivery stents: Abciximab–Kruppel-like Factor 4-plasmid dual-delivery TiO₂–coated coronary stents

Recently, we developed a novel drug and gene dual-delivery system for coronary stents using TiO₂, with nonpolymer thin film with high blood compatibility used for drug delivery, and a denatured polymer coating for local gene delivery. Our results suggested that this novel system could be useful for the dual delivery of a drug and gene in coronary stents and other biomedical devices. To analyze the inhibitory effect on ISR, both TiO₂-abciximab-Kruppel-like factor 4-plasmid-cobalt chromium (TAK-CC) and TiO₂-only cobalt chromium (T-CC) stents were used. On histomorphometric analysis after four weeks of implantation in a porcine coronary artery, the TAK-CC group had decreased ISR compared with the T-CC group (TAK-CC group: 26.38±10.79% vs. the T-CC group: 48.59±20.17%, n=6 in each, p<0.05). Neither the TAK-CC nor T-CC stent group showed fibrin deposition by Carstairs’ stain, and both groups showed accel-

Fig. 2. Comparison of the ISR area (mm²) between three types of stents, including the Akt-siRNA-embedded stent (adapted from Che et al. Biomaterials 2012;33:8548-56).⁸⁴ ISR: in-stent restenosis, BMS: bare-metal stent, HA: hyaluronic acid.
enerated re-endothelialization, as indicated by detectable anti-CD31-positive stained cells compared with a commercially available PES.\textsuperscript{30}

**Conclusion**

The conventional requirements for developing a new DES have been considered to include 1) the inhibitory efficacy of eluting agent against the development of NIH, 2) the stability of the coating agent on the metal stent strut, and 3) cost-effectiveness. However, currently, we must consider DESs with bioabsorbable polymers, such as the ssPEI polymer, in our gene-delivery stent, or polyactic acid, in the biolimus-A9-eluting stent; a polymer-free DES, such as the drug-filled stent by Medtronic; or the development of recent bioresorbable vascular scaffolds. We established a stent factory several years ago and are performing research on the Akt1 siRNA-embedded stent, which is based on biodegradable ssPEI polymer and genetic modification, as well as a drug and gene delivery stent, the TAK-CC. Notwithstanding these efforts, the development of a highly efficient domestic DES may require some time. With cooperation between medicine and mechanics, as well as industry and educational organizations, the fulfillment of these requirements will lead to a commercial domestic DES, benefiting numerous cardiovascular patients in Korea. These benefits would include cost-effective coronary stents due to lower taxes and expenses in the manufacture of coronary stents with safety and efficacy comparable to imported stents. In addition, we are confident that, in the near future, the safety and efficacy outcomes of domestic DESs will be better than those of imported stents.

**Acknowledgments**

This study was supported by a grant of the Regeneromics Research Center, Chonnam National University.

**References**

1. Forrester JS, Fishbein M, Helfant R, Fagin J. A paradigm for restenosis based on cell biology: clues for the development of new preventive therapies. J Am Coll Cardiol 1991;17:758-69.
2. Austin GE, Ratliff NB, Hollman J, Tabei S, Phillips DF. Intimal proliferation of smooth muscle cells as an explanation for recurrent coronary artery stenosis after percutaneous transluminal coronary angioplasty. J Am Coll Cardiol 1985;6:369-75.
3. Bae Y, Jeong MH, Jang YS, et al. Comparison of porcine coronary stent restenosis between MAC (Maximum Arterial Re-Creation) and Palmaz-Schatz stent. Korean Circ J 1998;28:59-96.
4. Giraldo AA, Esposo OM, Meis JM. Intimal hyperplasia as a cause of restenosis after percutaneous transluminal coronary angioplasty. Arch Pathol Lab Med 1985;109:173-5.
5. Ahn YK, Jeong MH, Kim JW, et al. Preventive effects of the heparin-coated stent on restenosis in the porcine model. Catheter Cardiovasc Interv 1999;48:324-30.
6. Hong YJ, Jeong MH, Ahn Y, Kang JC. The efficacy and safety of drug-eluting stents in patients with acute myocardial infarction: results from Korea Acute Myocardial Infarction (KAMIR). Int J Cardiol 2013;163:1-4.
7. Chen KY, Rha SW, Li YJ, et al. Triple versus dual antiplatelet therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 2009;119:3207-14.
8. Park KH, Jeong MH, Lee MG, et al. What is the optimal duration of triple anti-platelet therapy in patients with acute myocardial infarction undergoing drug-eluting stent implantation? J Cardiol 2011;57:53-60.
9. Lake DF, Briggs AD, Akporiaye ET. Immunopharmacology. In: Katzung BG editor. Basic & Clinical pharmacology. 12th ed. New York: McGraw Hill;2012. p.985-94.
10. Bonow RO, Mann DL, Zipes DP, Libby P, Braunwald E. Braunwald’s Heart Disease: A Textbook of Cardiovascular Medicine. Philadelphia, PA: Elsevier Saunders;2012.
11. Capila I, Linhardt RJ. Heparin-protein interactions. Angew Chem Int Ed Engl 2002;41:391-412.
12. Violex MC, Legrand VM, Reiber JH, et al. Heparin-coated Wiktor stents in human coronary arteries (MENTOR trial). MENTOR Trial Investigators. Am J Cardiol 2000;86:385-9.
13. Kim YJ, Kang JK, Huh MW, Yoon SC. Surface characterization and in vitro blood compatibility of poly (ethylene terephthalate) immobilized with insulin and/or heparin using plasma glow discharge. Biomaterials 2000;21:121-30.
14. Chen H, Chen Y, Sheardown H, Brook MA. Immobilization of heparin on a silicone surface through a heterobifunctional PEG spacer. Biomaterials 2005;26:7418-24.
15. Use of a monoclonal antibody directed against the platelet glycoprotein IIb/IIIa receptor in high-risk coronary angioplasty. The EPIC Investigation. N Engl J Med 1994;330:956-61.
16. Platelet glycoprotein IIb/IIIa receptor blockade and low-dose heparin during percutaneous coronary revascularization. The EPilogue Investigators. N Engl J Med 1997;336:1689-96.
17. Randomised placebo-controlled trial of abciximab before and during coronary intervention in refractory unstable angina: the CAPTURE Study. Lancet 1997;349:1429-35.
18. Inhibition of the platelet glycoprotein IIb/IIIa receptor with tirofiban in unstable angina and non-Q-wave myocardial infarction. Platelet Receptor Inhibition in Ischemic Syndrome Management in Patients Limited by Unstable Signs and Symptoms (PRISM-PLUS) Study Investigators. N Engl J Med 1998;338:1488-97.
19. Tam SH, Sassoli PM, Jordan RE, Nakada MT. Abciximab (ReoPro, chimeric 7E3 Fab) demonstrates equivalent affinity and functional blockade of glycoprotein IIb/IIIa and alpha(v)beta3 integrins. Circulation 1998;98:1085-91.
20. Reverter JC, Béguin S, Kessels H, Kumar R, Hemker HC, Collier BS. Inhibition of platelet-mediated, tissue factor-induced thrombin generation by the mouse/human chimeric 7E3 antibody. Potential implications for the effect of c7E3 Fab treatment on acute thrombosis and “clinical restenosis.” J Clin Invest 1996;98:863-74.

http://dx.doi.org/10.4070/kcj.2013.43.10.645
21. Shappell SB, Toman C, Anderson DC, Taylor AA, Entman ML, Smith CW. Mac-1 (CD11b/CD18) mediates adherence-dependent hydrogen peroxide production by human and canine neutrophils. J Immunol 1990;144:2702-11.

22. Simon DI, Xu H, Ortlepp S, Rogers C, Rao NK. 7E3 monoclonal antibody directed against the platelet glycoprotein IIb/IIIa cross-reacts with the leukocyte integrin Mac-1 and blocks adhesion to fibrinogen and ICAM-1. Arterioscler Thromb Vasc Biol 1997;17:528-35.

23. Mickelson JK, Ali MN, Kleiman NS, et al. Chimeric 7E3 Fab (ReoPro) decreases detectable CD11b on neutrophils from patients undergoing coronary angioplasty. J Am Coll Cardiol 1999;33:97-106.

24. Lefkovits J, Topol EJ. Platelet glycoprotein IIb/IIIa receptor antagonists in coronary artery disease. Eur Heart J 1996;17:9-18.

25. Pratt RE, Dzau VJ. Pharmacological strategies to prevent restenosis: lessons learned from blockade of the renin-angiotensin system. Circulation 1996;93:848-52.

26. Nakamura M, Funakoshi T, Arakawa N, Yoshida H, Makita S, Hiramori K. Effect of angiotensin-converting enzyme inhibitors on endothelium-dependent peripheral vasodilatation in patients with chronic heart failure. J Am Coll Cardiol 1994;24:1321-7.

27. Hirooka Y, Imaiizumi T, Masaki H, et al. Captopril improves impaired endothelium-dependent vasodilatation in hypertensive patients. Hypertension 1992;20:175-80.

28. Mancini GB, Henry GC, Macaya C, et al. Angiotensin-converting enzyme inhibition with quinapril improves endothelial vasomotor dysfunction in patients with coronary artery disease. The TREND (Trial on Reversing Endothelial Dysfunction) Study. Circulation 1996;94:258-65.

29. Packer L, Roy S, Sen CK. Alpha-lipoic acid: a metabolic antioxidant and potential redox modulator of transcription. Adv Pharmacol 1997;38:79-101.

30. Ziegler D, Hanefeld M, Ruhnau KJ, et al. Treatment of symptomatic diabetic polyneuropathy with the antioxidant alpha-lipoic acid: a 7-month multicenter randomized controlled trial (ALADIN III Study). ALADIN III Study Group. Alpha-Lipoic Acid in Diabetic Neuropathy. Diabetes Care 1999;22:1296-301.

31. Sung MJ, Kim W, Ahn SY, et al. Protective effect of alpha-lipoic acid in lipopolysaccharide-induced endothelial fractalkine expression. Circ Res 2005;97:880-90.

32. Lee KM, Park KG, Kim YD, et al. Alpha-lipoic acid inhibits fractalkine expression and prevents neointimal hyperplasia after balloon injury in rat carotid artery. Atherosclerosis 2006;189:106-14.

33. Ohlstein EH, Douglas SA, Sung CP, et al. Carvedilol, a cardiovascular drug, prevents vascular smooth muscle cell proliferation, migration, and neointimal formation following vascular injury. Proc Natl Acad Sci USA 1993;90:6189-93.

34. Sung CP, Arleth AJ, Ohlstein EH. Carvedilol inhibits vascular smooth muscle cell proliferation. J Cardiovasc Pharmacol 1993;21:221-7.

35. Sung CP, Arleth AJ, Eichman C, Truneh A, Ohlstein EH. Carvedilol, a multiple-action neurohumoral antagonist, inhibits mitogen-activated protein kinase and cell cycle progression in vascular smooth muscle cells. J Pharmacol Exp Ther 1997;283:910-7.

36. Fattori R, Piva T. Drug-eluting stents in vascular intervention. Lancet 2003;361:247-9.

37. Pruetz KD, Dujovne CA. Probuloc. Curr Atheroscler Rep 2000;2:47-57.

38. Tardif JC, Côté G, Lespérance J, et al. Probuloc and multivitamins in the prevention of restenosis after coronary angioplasty. Multivitamins and Probuloc Study Group. N Engl J Med 1997;337:365-72.

39. Watanabe K, Sekiya M, Ikeda S, Miyagawa M, Hashida K. Preventive effects of probuloc on restenosis after percutaneous transluminal coronary angioplasty. Am J Heart 1996;132(1 Pt 1):23-9.

40. Côté G, Tardif JC, Lespérance J, et al. Effects of probuloc on vascular remodeling after coronary angioplasty. Multivitamins and Protocol Study Group. Circulation 1999;99:30-5.

41. Schneider JE, Berk BC, Gravanis MB, et al. Probuloc decreases neointimal formation in a swine model of coronary artery balloon injury. A possible role for antioxidants in restenosis. Circulation 1993;88:628-37.

42. Waterman MA, Sundell CL, Kunsch C, Edwards D, Meng CQ, Medford RM. Chemistry and pharmacology of vascular protectants: a novel approach to the treatment of atherosclerosis and coronary artery disease. Am J Cardiol 2003;91:34A-40A.

43. Tardif JC, Grégoire J, Schwartz L, et al. Effects of AGI-1067 and probuloc after percutaneous coronary interventions. Circulation 2003;107:552-8.

44. Wakeyama T, Ogawa H, lida H, et al. Effects of candesartan and probuloc on restenosis after coronary stenting: results of insight of stent in-stent hyperplasia inhibition by new angiotensin II receptor antagonist (ISHIN) trial. Circ J 2003;67:519-24.

45. Logeart D, Prigent-Richard S, Jozefonvicz J, Letourneur D, Fucans, sulfated polysaccharides extracted from brown seaweeds, inhibit vascular smooth muscle cell proliferation. I. Comparison with heparin for antiproliferative activity, binding and internalization. Eur J Cell Biol 1997;74:376-84.

46. Kim JM, Cho EJ, et al. Effect of fucofuran for smooth muscle cell proliferation and neointima hyperplasia in a rabbit iliac artery in-stent restenosis model. Korean Circ J 2011;41:II-245. Abstract.

47. Liu Q, Ding J, Mante FK, Wunder SL, Baran GR. The role of surface functional groups in calcium phosphate nucleation on titanium foil: a self-assembled monolayer technique. Biomaterials 2002;23:3103-11.

48. Fu J, Ji J, Yuan W, Shen J. Construction of anti-adhesive and antibacterial multilayer films via layer-by-layer assembly of heparin and chitosan. Biomaterials 2005;26:6684-92.

49. Meng S, Liu Z, Shen L, et al. The effect of a layer-by-layer chitosan-heparin coating on the endothelialization and coagulation properties of a coronary stent system. Biomaterials 2009;30:2276-83.

50. Lee H, Dellatore SM, Miller WM, Messersmith PB. Mussel-inspired surface chemistry for multifunctional coatings. Science 2007;318:426-30.

51. Rich DH, Singh J. The Carbodiimide Method. In: Meienhofer, editor. The peptides. Academic Press;1979. p.241-61.

52. Bae IH, Park IK, Park DS, Lee H, Jeong MH. Thromboreistant and endothelialization effects of dopamine-mediated heparin coating on a stent material surface. J Mater Sci Mater Med 2012;23:1259-69.

53. Song SJ, Park YJ, Park J, et al. Preparation of a drug-eluting stent using
a TiO2 film deposited by plasma enhanced chemical vapour deposition as a drug-combining matrix. J Mater Chem 2010;20:4792-801.

54. Windheker S, Mayer I, De Pasquale G, et al. Stent coating with titanium-nitride-oxide for reduction of neointimal hyperplasia. Circulation 2001;104:928-33.

55. Tsyanov N, Maitz MF, Wieser E, Richter E, Reuther H. Correlation between blood compatibility and physical surface properties of titanium-based coatings. Surf Coat Technol 2005;200:1041-4.

56. Puskas JE, Muñoz-Robledo LG, Hoerr RA, et al. Drug-eluting stent coatings. Wiley Interdiscip Rev Nanomed Nanobiotechnol 2009;1:451-62.

57. Song SJ, Jung KW, Park YJ, et al. Nitrogen-doped TiO2 films as drug-binding matrices for the preparation of drug-eluting stents. J Mater Chem 2011;21:8168-77.

58. Packer L, Witt EH, Tritschler HJ. Alpha-Lipoic acid as a biological antioxidant. Free Radic Biol Med 1995;19:227-50.

59. Sim DS, Kwon JS, Kim YS, et al. Experience with Endothelial Progenitor Cell Capturing Aptamers for Coating of Intracoronary Stents in a Porcine Model. TERM 2009;6:555-61.

60. Stettler C, Wandel S, Alleman S, et al. Outcomes associated with drug-eluting and bare-metal stents: a collaborative network meta-analysis. Lancet 2007;370:937-48.

61. Stone GW, Moses JW, Ellis SG, et al. Safety and efficacy of sirolimus- and paclitaxel-eluting coronary stents. N Engl J Med 2007;356:998-1008.

62. Räber L, Magro M, Stefanini GG, et al. Very late coronary stent thrombosis of a newer-generation everolimus-eluting stent compared with early-generation drug-eluting stents: a prospective cohort study. Circulation 2012;125:1110-21.

63. Kedhi E, Joesof KS, McFadden E, et al. Second-generation everolimus-eluting and paclitaxel-eluting stents in real-life practice (COMPARE): a randomised trial. Lancet 2010;375:201-9.

64. Stone GW, Rizvi A, Newman W, et al. Everolimus-eluting versus paclitaxel-eluting stents in coronary artery disease. N Engl J Med 2010;362:1663-74.

65. Jensen LO, Thayssen P, Hansen HS, et al. Randomized comparison of everolimus-eluting and sirolimus-eluting stents in patients treated with percutaneous coronary intervention: the Scandinavian Organization for Randomized Trials with Clinical Outcome IV (SORT OUT IV). Circulation 2012;125:1246-55.

66. Kimura T, Morimoto T, Natsuaki M, et al. Comparison of everolimus-eluting and sirolimus-eluting coronary stents: 1-year outcomes from the Randomized Evaluation of Sirolimus-eluting Versus Everolimus-eluting stent Trial (RESET). Circulation 2012;126:1225-36.

67. Leon MB, Nikolsky E, Cutlip DE, et al. Improved late clinical safety with zotarolimus-eluting stents compared with paclitaxel-eluting stents in patients with de novo coronary lesions: 3-year follow-up from the ENDEAVOR IV (Randomized Comparison of Zotarolimus- and Paclitaxel-Eluting Stents in Patients With Coronary Artery Disease) trial. JACC Cardiovasc Interv 2010;3:1043-50.

68. Park DW, Kim YH, Yun SC, et al. Comparison of zotarolimus-eluting stents with sirolimus- and paclitaxel-eluting stents for coronary revascularization: the ZEST (comparison of the efficacy and safety of zotarolimus-eluting stent with sirolimus-eluting and paclitaxel-eluting stent for coronary lesions) randomized trial. J Am Coll Cardiol 2010;56:1187-95.

69. Bangalore S, Kumar S, Fusaro M, et al. Short- and long-term outcomes with drug-eluting and bare-metal coronary stents: a mixed-treatment comparison analysis of 117 762 patient-years of follow-up from randomized trials. Circulation 2012;125:2873-91.

70. Camenzind E, Wijns W, Mauri L, et al. Stent thrombosis and major clinical events at 3 years after zotarolimus-eluting or sirolimus-eluting coronary stent implantation: a randomised, multicentre, open-label, controlled trial. Lancet 2012;380:1396-405.

71. Lim SY, Bae EH, Jeong MH, et al. Effect of alpha lipoic acid in a porcine in-stent restenosis model. J Cardiol 2009;54:375-85.

72. Kim W, Jeong MH, Hong YJ, et al. The long-term clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (Abciximab: Reopro) coated stent in patients with coronary artery disease. Korean J Intern Med 2004;19:220-9.

73. Kim W, Jeong MH, Kim KH, et al. The clinical results of a platelet glycoprotein IIb/IIIa receptor blocker (abciximab: ReoPro)-coated stent in acute myocardial infarction. J Am Coll Cardiol 2006;47:933-8.

74. Hong YJ, Jeong MH, Hwang SH, et al. Impact of postprocedural minimum stent area on long-term results following abciximab-coated stent implantation: an intravascular ultrasound analysis. Int J Cardiol 2007;123:23-8.

75. Hong YJ, Jeong MH, Lee SR, et al. Anti-inflammatory effect of abciximab-coated stent in a porcine coronary restenosis model. J Korean Med Sci 2007;22:802-9.

76. Kim SS, Hong YJ, Jeong MH, et al. Two-year clinical outcome after abciximab-coated stent implantation in patients with coronary artery disease. Circ J 2010;74:442-8.

77. Hong YJ, Jeong MH, Song SJ, et al. Effects of ramiprilat-coated stents on neointimal hyperplasia, inflammation, and arterial healing in a porcine coronary restenosis model. Korean Circ J 2011;41:535-41.

78. Kim JM, Kim JH, Jeong MH, et al. Fabrication and evaluation of a fucoidan-coated stent in a porcine coronary restenosis model. Korean Circ J 2012;42:112-20. Abstract.

79. Lim KS, Hong YJ, Hachinohe D, et al. Effect of a dual drug-coated stent with abiciximab and alpha-lipoic Acid in a porcine coronary restenosis model. Korean Circ J 2011;41:241-7.

80. Räber L, Kelbæk H, Ostojic M, et al. Effect of biolimus-eluting stents with biodegradable polymer vs bare-metal stents on cardiovascular events among patients with acute myocardial infarction: the COMFORTABLE AMI randomized trial. JAMA 2012;308:777-87.

81. Smits PC, Hofma S, Togni M, et al. Abluminal biodegradable polymer biolimus-eluting stent versus durable polymer everolimus-eluting stent (COMPARE II): a randomised, controlled, non-inferiority trial. Lancet 2013;381:651-60.

82. Stefanini GG, Kalesan B, Serruys PW, et al. Long-term clinical outcomes of biodegradable polymer biolimus-eluting stents versus durable polymer sirolimus-eluting stents in patients with coronary artery disease (LEADERS): 4 year follow-up of a randomised non-inferiority trial. Lancet 2011;378:1940-8.

83. Stefanini GG, Byrne RA, Serruys PW, et al. Biodegradable polymer
drug-eluting stents reduce the risk of stent thrombosis at 4 years in patients undergoing percutaneous coronary intervention: a pooled analysis of individual patient data from the ISAR-TEST 3, ISAR-TEST 4, and LEADERS randomized trials. *Eur Heart J* 2012;33:1214-22.

84. Che HL, Bae IH, Lim KS, et al. Suppression of post-angioplasty restenosis with an Akt1 siRNA-embedded coronary stent in a rabbit model. *Biomaterials* 2012;33:8548-56.

85. Jiang HL, Hong SH, Kim YK, et al. Aerosol delivery of spermine-based polyamino ester/Akt1 shRNA complexes for lung cancer gene therapy. *Int J Pharm* 2011;420:256-65.

86. Jere D, Arote R, Jiang HL, Kim YK, Cho MH, Cho CS. Biodegradable nano-polymeric system for efficient Akt1 siRNA delivery. *J Nanosci Nanotechnol* 2010;10:3366-9.

87. Jiang HL, Xu CX, Kim YK, et al. The suppression of lung tumorigenesis by aerosol-delivered folate-chitosan-graft-polyethylenimine/Akt1 shRNA complexes through the Akt signaling pathway. *Biomaterials* 2009;30:5844-52.

88. Duguay D, deBlois D. Differential regulation of Akt, caspases and MAP kinases underlies smooth muscle cell apoptosis during aortic remodelling in SHR treated with amlodipine. *Br J Pharmacol* 2007;151:1315-23.

89. Jere D, Jiang HL, Kim YK, et al. Chitosan-graft-polyethylenimine for Akt1 siRNA delivery to lung cancer cells. *Int J Pharm* 2009;378:194-200.

90. Kwon JC, Song SJ, Yang EJ, et al. Novel abciximab-Kruppel-like factor 4-plasmid dual-delivery titanium dioxide-coated coronary stent. *Int J Cardiol* 2013. [Epub ahead of print]